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ABSTRACT
INTRODUCTION: Liver metastases are the most common 
complication to colorectal cancer, and the presence of 
metastatic disease severely impacts the overall prognosis 
of the disease. Since the diagnostic work-up of 
metastasised colorectal cancer has undergone tremendous 
changes in past decades, an impact on the incidence of 
metastatic disease is anticipated. The aim of this study was 
to evaluate the incidence and prognosis of liver metastasis 
in patients with colorectal cancer.
METHODS: From 1 January 2005 to 31 December 2011, all 
patients with a primary diagnosis of colorectal cancer were 
identified. Data on metastatic dissemination to the liver 
were collected from medical charts. Patients were followed 
until death or the end of the study period (31 December 
2016). 
RESULTS: Among the total study population of 1,672 
patients, 23.6% of patients were diagnosed with liver 
metastases. The incidence of synchronous and 
metachronous metastases was 16% and 7.7%, respectively. 
Patients with synchronous and metachronous metastases 
had a median survival of ten (95% confidence interval (CI): 
7.5-12.5) and 43 (95% CI: 35.8-50.2) months, respectively, 
compared with a median survival of 86 (95% CI: 73.5-98.5) 
months for patients without liver metastases. 
CONCLUSIONS: The incidence of synchronous metastases 
has remained high despite improved diagnostic technology. 
Patient survival remains significantly lower when metastatic 
disease is present, even though treatment options for liver 
metastases have improved. 
FUNDING: none.
TRIAL REGISTRATION: not relevant.
Colorectal cancer (CRC) is the fourth leading cause of 
cancer-related death worldwide [1]. In Denmark, co-
lonic cancer is the third most common cancer among 
men and women alike [2]. The incidence of CRC has 
slowly increased in Denmark, and the introduction of a 
national screening programme in 2014 has led to a ra-
pid increase in the recorded incidence of CRC [3]. 
The liver is the first and most common site of dis-
semination in patients with CRC [4]. Presence of colo-
rectal liver metastases (CRLM) at the time of diagnosis 
(synchronous) or further along the disease pathway 
(metachronous) is an important prognostic factor for 
patients with CRC [5, 6]. Studies having investigated 
the natural history of CRC with metastatic disease to 
the liver have found a median survival time from seven 
to eleven months [5, 7]. In addition, a poor survival 
outcome was related to the presence of synchronous 
metastases (SM) [8]. Previously, it was a common  
understanding that up to 25% of patients with CRC 
would have SM at the time of diagnosis and that 
another 25% would develop liver metastases in the 
course of their disease [4, 9]. However, more recent 
studies of patients with CRC and metastatic disease 
have shown a much lower incidence of both synchron-
ous (15-19%) and metachronous liver metastases 
(MM) (13-14%) [4, 10, 11]. 
The aim of this study was to investigate the inci-
dence, survival and prognosis of CRLM in a population 
of patients with CRC treated at a colorectal cancer cen-
tre in eastern Denmark. Furthermore, we sought to in-
vestigate the significance of distant metastases in add -
ition to CRLM.
METHODS
A retrospective search was conducted using the Inter-
national Classification of Disease (ICD)-10 codes for 
cancers of the colon and rectum to identify all patients 
referred with a verified diagnosis of CRC (codes DC18 
and DC20). Another group of patients was identified 
through a national database including information 
about all patients registered with verified CRC. Data 
were retrieved after achieving the relevant approval 
from the local administrator of the database and was 
approved by the Danish Data Protection Agency. Pa-
tients were included from a high-volume CRC treat-
ment centre, Herlev and Gentofte University Hospitals, 
covering an admission area of nearly 425,000 inhabit-
ants in eastern Denmark. Data collection was limited to 
a seven-year period from 1 January 2005 to 31 Decem-
ber 2011 with follow-up until 31 December 2016. 
All information was extracted manually from med-
ical records by the authors. The information included: 
date of diagnosis, tumour location, tumour stage and 
presence or absence of liver metastases at the time of 
the primary cancer diagnosis. Moreover, the following 
information was obtained during the follow-up period 
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for patients with CRLM: extent of hepatic involvement, 
type of imaging used for diagnosis and treatment; and 
the presence of lung and peritoneal metastases was re-
gistered as distant metastases for patients with CRLM. 
Liver metastases were considered synchronous if meta-
static disease was present within six months of the pri-
mary CRC diagnosis, and metachronous if present 
more than six months after the primary diagnosis. For 
patients without SM or MM at the end of 2011, the 
5-year follow-up included information only regarding 
the incidence of liver metastases. 
The tumour-node-metastasis (TNMV) stage of the 
primary CRC was obtained from the pathologist’s re-
port and/or from diagnostic images such as CT, MRI or 
PET-CT. We excluded patients with recurrent disease 
or a diagnosis of CRC prior to 1 January 2005 along 
with patients who had liver metastases of unknown ori-
gin. A large number of patients was omitted due to du-
plicates in the ICD10 codes and in the database. Most 
of the excluded cases were excluded due to incomplete 
medical records and a smaller part of the cases were in-
accessible since the patients were primarily diagnosed 
at other hospitals.
The vital status of the patients was obtained from 
the Danish Civil Registration database. The register 
contains updated data such as, e.g., the date of birth 
and death and the status of emigration of every Danish 
resident. Patients were followed until death, immigra-
tion, or until the end of the study whichever came first.
Statistics
The statistical analyses were conducted using SPSS ver-
sion 22.0 (IBM SPSS, Armonk, NY, USA). 
Survival time was calculated from the time of the 
CRC diagnosis until death or the end of the follow-up 
period. Survival for patients with SM and MM was cal-
culated by the Kaplan-Meier method, and survival cur-
ves were constructed with data presented as medians 
with 95% confidence intervals (CIs). To evaluate base-
line characteristics, the chi-squared test or Fisher’s 
exact test was applied for dichotomous variables. To 
evaluate prognostic variables for overall survival, a 
multivariate analysis was applied using Cox’s propor-
tional hazards model with data presented as hazard ra-
tios (HRs) with 95% CI. A two-sided p-value ≤ 0.05 
was considered statistically significant. 
Trial registration: not relevant.
RESULTS
A total of 2,193 patients with a CRC diagnosis were re-
gistered during the seven-year study period. After ex-
clusion, a total of 1,672 patients were eligible for 
further analyses. Patient characteristics are summar-
ised in Table 1. A total of 395 (23.7%) patients were 
diagnosed with CRLM. The overall incidence of SM was 
16.0%, and the incidence of MM was 7.7%. Of patients 
with SM and MM, distant metastases to the peritoneum 
and lungs were present in 39% and 32% of cases, re-
spectively (Table 1).
Survival and mortality
Overall, patients with CRLM had a median survival of 
52 months (95% CI: 44.8-59.1 months). Patients with 
SM and MM had a median survival of 11 months  
(95% CI: 6.3-15.7 months) and 36 months (95% CI: 
26.7-45.3 months), respectively, compared with a me-
dian survival of 86 months (95% CI: 73.5-98.5 months) 
for patients without CRLM at the end of follow-up.  
Patients without CRLM had a significantly better survi-
val than patients with SM (p < 0.001) and MM (p < 
0.001). Survival analyses showed a lower survival for 
patients with SM than for patients with MM and with-
out CRLM (Figure 1). Cases with presence of distant 
metastases in addition to CRLM showed a median 
survival of 12 months (8.7-15.3) for patients with SM 
and 41 months (95% CI: 33.2-48.8 months) for MM  
patients.  
Of the total population of 1,672 patients, 801 pa-
tients were eligible for five-year survival analyses. For 
patients with SM the five-year survival rate was 6.6%, 
and for patients with MM it was 32.4% compared with 
56.9% for patients without CRLM.  
Management and treatment
A total of 66% of the patients with CRLM underwent 
surgery for their primary tumour (Table 1). A greater 
number of patients with SM received symptomatic  
treatment (32.6%), by e.g. colonic stenting, compared 
with patients with MM (3.1%) (p < 0.001). 
A total of 10.6% of the 395 patients with CRLM  
underwent liver resection as treatment for CRLM. 
Radio frequency ablation (RFA) was the selected treat-
ment option in 9.4%, and 31.4% of the patients were 
treated with chemotherapy alone. Survival analyses 
(unadjusted) showed that patients treated with liver 
resection or RFA had a survival that was superior to 
that of patients treated with chemotherapy only or pa-
tients receiving non-curative treatment (p < 0.001) 
(Figure 2). Multivariate analyses evaluating the impact 
of CRLM treatment and overall survival found an equal 
HR for liver resection and chemotherapy only (p = 
0.102), whereas the prognosis for no treatment was 
significantly poorer (p < 0.001) (Table 2). Further 
sub-analyses were not conducted due to missing data 
(Table 1).
DISCUSSION
In the present study, a total of 395 (23.5%) patients 
were diagnosed with CRLM. The incidence of SM was 
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TABLE 1
Patient characteristics.
 All patients
(N = 1,658a)
Cancer coli
(nsubtot = 1,123)
Cancer recti
(nsubtot = 535)
Synchronous liver metastases
(nsubtot = 267)
Metachronous liver metastases
(nsubtot = 128d)
Sex, n (%)
Male 817 (49.3) 505 (45.0) 312 (58.3) 135 (50.6) 78 (61.0)
Female 841 (50.7) 618 (55.0) 223 (41.7) 132 (49.4) 50 (39.0)
Age, yrs, mean (± SD) 73.9 (± 11.2) 74.5 (± 11.2) 72.6 (± 11.2) 70.3 (± 11.8) 73.2 (11.9)
Primary tumour classification, n (%)
T-stage:
T0     9 (0.5)     3 (0.3)     6 (1.1)     1 (0.4) 0 (0.0)
T1   58 (3.5)   39 (3.5)   19 (3.6)     2 (0.8) 2 (1.6)
T2 159 (9.6)   57 (5.1) 102 (19.1)     6 (2.3) 12 (9.4)
T3 787 (47.5) 542 (48.3) 245 (45.8)   89 (33.3) 69 (53.9)
T4 300 (18.1) 255 (22.7)   45 (8.4)   65 (24.3) 31 (24.2)
N/Ab 345 (20.8) 227 (20.2) 118 (22.1) 104 (39.0) 14 (10.9)
N-stage:
N0 694 (41.9) 462 (41.1) 232 (43.4)   43 (16.1) 41 (32.0)
N1 356 (21.4) 246 (21.9) 110 (20.6)   60 (22.5) 40 (31.3)
N2 248 (15.0) 182 (16.2)   66 (12.3)   57 (21.3) 31 (24.2)
N/Ab 360 (21.7) 233 (20.7) 127 (23.7) 107 (40.1) 16 (12.5)
V-stage:
V0 673 (40.6) 452 (40.2) 221 (41.3)   52 (19.5) 43 (33.6)
V1 325 (19.6) 255 (22.7)   70 (13.1)   67 (25.1) 42 (32.8)
V2   11 (0.7)     8 (0.7)     3 (0.6)     2 (0.7) 2 (1.6)
N/Ab 649 (39.1) 408 (36.3) 241 (45.0) 146 (54.7) 41 (32.0)
Location of CRLM, n (%) 
Left liver lobe – – –   17 (6.4)   4 (3.1)
Right liver lobe – – –   64 (24.0) 17 (13.3)
Both – – – 180 (67.4) 11 (8.6)
N/A – – –     6 (2.3) 96 (75.0)
Number of CRLM, n (%)
Solitary – – –   44 (16.5)   12 (9.4)
Multiple – – – 188 (70.4)   16 (12.5)
N/A – – –   35 (13.1) 100 (78.1)
Means of diagnoses, n (%)
Abdominal CT – – – 180 (67.4) 89 (69.5)
Ultrasound – – – 100 (37.5) 22 (17.2)
PET/CT – – –   32 (12.0) 13 (10.2)
Operative findings – – –   54 (20.2)   4 (3.1)
Treatment for primary tumour, n (%)
Resection – – – 143 (53.6) 118 (92.2)
Palliative surgeryc – – –   37 (13.9)     6 (4.7)
Symptomatic treatment – – –   87 (32.6)     4 (3.1)
Treatment for CRLM, n (%)
Liver resection – – –   31 (11.6) 11 (8.6)
Radio frequency ablation – – –   29 (10.9)   8 (6.3)
Chemotherapy – – – 100 (37.5) 24 (18.8)
N/A – – – 107 (40.1) 85 (66.4)
Distant metastases to other organs, n (%)
Pulmonary – – – 75 (28.1) 33 (25.8)
Peritoneum – – – 30 (11.2)   8 (6.3)
N/A – – –   0 (0.0) 23 (18.0)
CRLM = colorectal liver metastases; N/A = not applicable; SD = standard deviation.
a) 14 patients with simultaneous colonic and rectal cancer are not included in baseline characteristics. b) Stage not available or tumour was not resected.
c) Includes endoscopic insertion of colonic stents.d) Missing data from 12 patients.
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16.0%, which is in line with other studies which have 
reported an incidence in the 14.5-18.9% range [4, 10, 
11], but also remarkably lower than Bengmark et al 
who found a much higher incidence (24.5%) in 1968 
[9]. These ambiguities may have been caused by dif-
ferences in the definition of liver metastases, which  
varies among countries. Some studies defined CRLM as 
synchronous when metastases were present within the 
first three months from the primary diagnosis; others 
considered CRLM to be synchronous when present un-
til one year after diagnosis; and others failed to report 
the definition used [4, 8, 11-13]. In the present study, 
metastases were considered synchronous until six 
months after the primary CRC diagnosis and meta-
chron ous when detected later than six months after the 
primary diagnosis. Other factors influencing the inci-
dence may be related to the improvement of the diag-
nostic work-up, including imaging techniques which 
have yielded a better and more accurate diagnostic 
work-up earlier in the disease process. This would lead 
to an anticipated increase in the incidence of SM, while 
more aggressive treatment strategies, such as early sur-
gical intervention combined with more potent chemo-
therapy, may decrease the incidence of SM, contribu-
ting to a steady SM incidence.  
The incidence of MM demonstrated in the present 
study was 7.7%. In comparison, other studies have re-
ported the MM incidence to be 12.8-14% [4, 10, 11]. 
However, the discrepancy in the definition of MM in 
the literature affects the incidence and may partly ex-
plain our results. Furthermore, as this was a retrospect-
ive study, a certain degree of selection bias must be 
considered as not all patients with recurrent disease or 
MM were diagnosed or registered.   
The five-year survival for patients with SM in this 
study was 6.6%, which is in line with the literature  
(3-11%) [11, 14]. Also, the five-year survival rate for 
patients with MM was 32.4%, which is higher than re-
ported by other studies (12.8-20%) [4, 11, 14]. These 
differences may be caused by the differences in the MM 
definition but also by the above-mentioned risk of bias. 
However, it may also be a question of lead-time bias, 
meaning that the survival may be similar to those re-
ported in the literature, but that the metastases were 
detected earlier than in other studies. 
The survival and prognosis for patients with CRLM 
depend on multiple factors. The extent of liver involve-
ment represents an important factor; yet, the prognosis 
may also depend on the total extent of metastatic dis-
ease like extra-hepatic metastases and multiple liver le-
sions [7, 15]. This may reflect that patients with multi-
ple liver metastases often have a larger tumour burden, 
corresponding to more advanced disease. Our study 
found a similar overall survival for patients with CRLM 
with and without distant metastases. However, our 
data on liver lesions were limited, and interpretation 
should be done with caution (Figure 1). 
Surgical resection of CRLM has shown to improve 
survival substantially with a reported three-year sur-
vival rate of 63-70% [10, 16]. Furthermore, a recent 
study investigating unresectable CRLM found a super-
FIGURE 1
Overall survival of colo-
rectal cancer patients 
with and without liver 
metastases.
 
CRLM = colorectal liver  
metastases; MM = meta-
chronous liver metastases; 
SM = synchronous liver 
metastases.
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FIGURE 2
Overall survival by  
treatment for colorectal 
cancer patients with 
liver metastases. 
 
RFA = radio frequency  
ablation.
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ior survival in patients randomised to standard practice 
in addition to local treatment (surgical or RFA) com-
pared with patients receiving standard care (chemo-
therapy) [17]. In our study, adjusted multivariate  
analyses showed that overall survival was similar re-
gard less of treatment with surgery/RFA or chemo-
therapy. However, once again, our results must be  
interpreted with caution due to the extent of missing 
data. Another interesting topic is whether the imple-
mentation of CRC screening will have an impact on the 
number of patients detected with metastatic disease, 
including CRLM. A recent study found that screening 
detects an increase of CRC in earlier stages [18], which 
is evidently linked to a better prognosis owing to earlier 
treatment and an anticipated reduction in the inci-
dence of metastatic disease, including liver metastases. 
On the other hand, a screening programme is costly 
and may entail a risk of over-diagnosing colonic adeno-
mas with no obvious malignant potential. Thus, pa-
tients may be enrolled in screening programmes with 
little benefit. Yet, hard evidence is lacking, and further 
investigations should be considered [19]. 
The present study has considerable limitations  
caused by its retrospective design. Operation notes, 
medical charts, missing data and registrations can  
leave room for ambiguous interpretation. In the pre-
sent study, each chart was studied only by one of the 
authors, without crosschecking, all of which may result 
in selection bias since the information retrieved relies 
on correct record keeping by health providers. The 
ICD10 disease coding system was applied to identify 
patients with CRC, and inaccurate coding cannot be  
ruled out. Hence, some patients with CRC may have 
been missed, adding to the risk of selection bias. 
Moreover, changes in the histological classification of 
the primary tumour from Dukes to TNMV may generate 
problems with comparing results throughout the study 
period. Some patients were excluded due to difficulties 
in accessing their medical charts because of a merging 
of hospital departments where patients were enrolled 
in 2007. Furthermore, as some patients in our cohort 
received parts of their treatments at other hospitals, 
their medical records were not available to the authors. 
In addition, some patients may never have received  
treatment and may therefore not have been registered. 
Also, in some cases, it was difficult to determine the 
exact time of diagnosis for SM and MM due to a delay 
in imaging interpretation from other hospital depart-
ments. Nevertheless, this study represents a large co-
hort of patients with CRLM and owing to the Danish 
Civil Registration, the follow up is considered highly 
accurate.
CONCLUSIONS
In this study population, a total of 23.6% patients with 
CRC were diagnosed with liver metastases, and the in-
cidence of patients with SM was 16.0% and the inci-
dence of patients with MM was 7.7%. The incidence of 
SM remains high with poor survival outcomes com-
pared with MM patients. An interesting question for fu-
ture research is whether the national screening pro-
gramme for CRC will have a positive impact on this 
matter. 
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